The tweet was deleted by the author.
But we saved everything 🙂.
Abbott introduced a new dual glucose and ketone sensing technology for diabetes management. The stock edges lower on the day, trading at $103.82.
Abbott introduced a two-in-one continuous glucose ketone sensing technology aimed at people living with diabetes. The device was recognized as a CES Innovation Awards Honoree. The product is intended to offer a more complete approach to diabetes care by allowing users to monitor both glucose and ketone levels.
View post on X Loading...
Price lost the MA-50 at $103.88 during the session after closing above it. Shares of Abbott are sitting right at resistance from that level, within a split daily structure where price remains below the MA-20 and MA-50 but above the MA-200. Stoch RSI is in oversold territory, a stretched reading that limits room for further downside. The trading action has been contained within a narrow range over the past week.
Traders should watch whether price can close above $103.88 to confirm buyers are willing to follow through. The price briefly moved above that level but closed below it by the end of the session. Even so, for the coming trading week, there is a 48% chance of upside and a 52% chance of downside, with shares expected to trade between $100.59 and $107.04. A move above $103.88 would confirm acceptance, while a drop below $103.22 would indicate the move is being faded. On the weekly chart the longer-term picture stays negative.
Earlier, analysts noted that Abbott maintained a broadly bullish technical posture despite caution around near-term overbought conditions and the potential for a short-term pullback. The introduction of its new dual glucose and ketone sensor adds a significant development to the story, but with shares testing critical support, traders should closely monitor $103.22 as a potential tipping point for renewed downward momentum.